Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Technology, Oil & Gas and Financials sectors led shares higher. At the close in NYSE, the Dow...
Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Consumer Services, Oil & Gas and Telecoms sectors led shares higher. At the close in NYSE, the...
QIAGEN N.V. (NYSE:QGEN) has unveiled its latest therascreen FGFR RGQ RT-PCR Kit (therascreen FGFR Kit) in the United States. This kit will be used as a companion diagnostic to...
Twist Bioscience Corporation (NASDAQ:TWST) was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more...
Advaxis, Inc. (NASDAQ:ADXS) announced encouraging updated data from its ongoing phase I/II study — KEYNOTE-046 — evaluating its pipeline candidate, ADXS-PSA, in...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Buy||Buy||Buy||Strong Sell||Strong Sell|
|Technical Indicators||Neutral||Strong Buy||BUY||Sell||Strong Sell|
|Summary||Neutral||Strong Buy||Buy||Strong Sell||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Downside Gap Three Methods||1W||2||Sep 29, 2019|
|Bullish doji Star||1D||2||Oct 11, 2019|
|Abandoned Baby Bearish||1D||3||Oct 10, 2019|
|Bank of America||29.73||30.24||29.11||+0.59||+2.02%||78.20M||15:59:59|
|Berkshire Hathaway B||209.38||210.15||207.57||+1.47||+0.71%||2.99M||15:59:59|
Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.Read More
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.